Advertisement: TTP Killer 50
6 August, 2019 - 12:14 By Tony Quested

Bicycle Therapeutics revamps board to oversee fresh growth spurt

Bicycle Therapeutics plc, which is pioneering a new class of therapeutics based on its proprietary bicyclic peptide technology, has unveiled key changes to the board as it enters a new period of growth on both sides of the Atlantic.

The revamp sees the appointment of two heavyweight new directors – biopharma big hitters Richard Kender and Janice Bourque – and the departure of four board members. 

CEO Kevin Lee said: “We are delighted to welcome Richard and Janice to the board and look forward to their leadership during this pivotal time of growth for Bicycle. 

“As a newly-public company with a rapidly advancing pipeline of oncology programs, Bicycle will benefit from their business development and financing expertise, as well as their deep industry knowledge.”

In the wake of a successful IPO on Nasdaq, the board has begun to implement an orderly transition, which is expected to occur over the coming year.

It will result in a reduction in board size, while enhancing its scientific and US public company board expertise. 

Deborah Harland (SR One) has indicated her intent to resign, following the next board meeting, on September 27. Michael Anstey (Cambridge Innovation Capital), Bosun Hau (Tybourne Capital Management) and Carolyn Ng (Vertex Ventures HC) have indicated their intent to resign on June 30, 2020.

Pierre Legault, chairman of the board, said: “As we welcome Richard and Janice we also would like to thank Debbie, Mike, Bosun and Carolyn for their services to the company. 

“These individuals brought a wealth of expertise that helped advance our pipeline and supported us through our IPO in May. With these changes, we believe the board remains well-equipped to support Bicycle’s development as a public company.”

Richard Kender has had an extensive career in the pharmaceutical industry, most recently serving as senior VP of Business Development and Corporate Licensing at Merck & Co., Inc. from 2000 until his retirement in 2013. 

During his career at Merck, he was greatly influential across business development, licensing and in finance roles that supported the domestic and international research, commercial and manufacturing divisions.

Janice Bourque is a managing director in Hercules Capital’s life sciences group and brings more than 25 years of life science experience and a focus on emerging growth stage companies. 

She has consulted for Commons Capital, served as senior VP and group head Life Sciences at Comerica Bank and was president and CEO of the Massachusetts Biotechnology Council.

Newsletter Subscription

Stay informed of the latest news and features